Adma Biologics (ADMA) closed the most recent trading day at $9.16, moving +2.35% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.72%. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 1.12%.
Heading into today, shares of the infectious disease drug developer had gained 12.3% over the past month, lagging the Medical sector's gain of 12.48% and outpacing the S&P 500's loss of 0.9%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. In that report, analysts expect Adma Biologics to post earnings of $0.16 per share. This would mark year-over-year growth of 6.67%. Meanwhile, our latest consensus estimate is calling for revenue of $125.77 million, up 3.11% from the prior-year quarter.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.82 per share and revenue of $535 million. These results would represent year-over-year changes of +36.67% and +4.87%, respectively.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.38% lower. Adma Biologics is holding a Zacks Rank of #5 (Strong Sell) right now.
Looking at its valuation, Adma Biologics is holding a Forward P/E ratio of 10.91. This expresses a discount compared to the average Forward P/E of 21.56 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 150, putting it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).